FILE - This December 2022 image provided by Eisai shows vials and packaging for their medication Leqembi. The first drug shown to slow Alzheimer’s disease hit the U.S. market in 2023, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. (Eisai via AP, File)
Scott Berkheiser, who has Alzheimer's disease, stands for a portrait at his home Friday, April 5, 2024, in Venice, Fla. Insurance denials delayed Berkheiser’s first Leqembi infusion a few months until last December. He said the drugmaker eventually agreed to give it to him for free while he makes co-payments for the infusions. “It was a little crazy,” he said. “It seemed like it was kind of a game that must make sense for some monetary reason.” (AP Photo/Chris O'Meara)
Scott Berkheiser, 57, who has Alzheimer's disease, sits for a portrait at his home Friday, April 5, 2024, in Venice, Fla. Insurance denials delayed Berkheiser’s first Leqembi infusion a few months until last December. He said the drugmaker eventually agreed to give it to him for free while he makes co-payments for the infusions. “It was a little crazy,” he said. “It seemed like it was kind of a game that must make sense for some monetary reason.” (AP Photo/Chris O'Meara)